Our Take
May was strategically quiet on licensing but structurally loud: big pharma is consolidating rare disease depth (Angelini, Bayer, UCB) and vaccine platforms (Lilly's three buys), while BMS is outsourcing early oncology to China—a sign that early-stage drug discovery is shifting outside the U.S.
Why it matters
Rare disease, vaccines, and cell therapies are now acquisition priorities for top-tier pharma, not just partnerships. If this pattern holds through Q3, it signals a structural reallocation of R&D spend away from in-house labs toward platform consolidation and geographic diversification.
Do this week
Biotech: map your platform's fit against Angelini (rare neuro), UCB (T-cell engagers), and Lilly's vaccine stack before your Series C—acquirer thesis is now explicit.
The seven deals: who bought whom and for how much
May 2026 saw seven multibillion-dollar acquisitions across biotech, anchored by two standout moves:
Angelini Pharma's $4.1 billion acquisition of Catalyst Pharmaceuticals (company-reported) is the largest. The Italian neurology and mental health company gains Catalyst's rare disease platform and a direct foothold in the U.S. neurological rare disease market. This is not a standalone compound buy; it is a platform consolidation.
Bayer's $2.45 billion acquisition of Perfuse Therapeutics (company-reported) brings the rights to PER-001, a small molecule endothelin receptor antagonist in phase 2 for glaucoma and diabetic retinopathy. The deal includes $300 million upfront and undisclosed milestone payments. This marks Bayer's first acquisition of 2026.
UCB's $2.2 billion purchase of Candid Therapeutics (company-reported) adds a pipeline of T-cell engagers. UCB already fields T-cell engagers, monoclonal antibodies, and cell therapies, so this expands a core competency rather than opening a new one.
Eli Lilly's $3.8 billion vaccine shopping spree (company-reported) involved three separate acquisitions: Curevo for up to $1.5 billion (lead candidate amezosvatein, an adjuvanted shingles vaccine), LimmaTech Biologics for up to $780 million (bacterial vaccine platform targeting drug resistance), and Vaccine Company for up to $1.55 billion (EBV vaccine using in vivo nanoparticle antigen presentation). Lilly also acquired DNA therapeutics company Engage Bio for up to $202 million for its tethosome technology, which uses lipid nanoparticles to deliver DNA and increase expression more than 100-fold (company-reported).
On the licensing side, Bristol Myers Squibb's $15.2 billion deal with Hengrui Pharma (company-reported) is the month's largest single pact. Hengrui hands over worldwide rights to 13 early-stage oncology, hematology, and immunology programs (excluding China, Hong Kong, and Macau). BMS pays $600 million upfront, $175 million after one year, another $175 million in 2028, plus milestone payments.
Two additional licensing deals landed in the antibody-drug conjugate space: Pfizer and Innovent Biologics agreed to develop 12 ADCs and multispecific antibodies (Innovent receives $650 million upfront and up to $9.85 billion in milestone payments, company-reported), and Regeneron partnered with Parabilis Medicines to combine Helicon peptides with antibody engineering ($125 million upfront and equity, plus up to $2.2 billion in further milestones, company-reported).
Platform consolidation, not fill-in-the-gaps M&A
What distinguishes May is the absence of bolt-on acquisitions. Angelini, UCB, and Bayer are all buying entire platforms or lead candidates in defined therapeutic areas—rare disease, T-cell immunity, eye disease—not licensing one molecule to round out a portfolio. This suggests that big pharma is treating rare disease and advanced immunotherapy as core capabilities worth owning, not outsourcing.
Lilly's vaccine consolidation is equally strategic. Three acquisitions in one month (Curevo, LimmaTech, Vaccine Company) point to a coordinated platform build in viral and bacterial vaccines. These are not independent bets; they are layers of a single thesis.
BMS's $15.2 billion Hengrui deal reveals a different risk calculus: outsource early-stage oncology discovery to China, retain in-house late-stage execution and commercialization in the U.S. and Europe. For a company that once dominated early-stage oncology internally, this is a structural shift.
What to watch next
The licensing deal volume was lower in May than earlier in 2026, suggesting that deal-making has shifted from the licensing layer (option on one program) to the M&A layer (acquisition of teams, platforms, and pipeline depth). If this continues through June and July, expect acquirer thesis statements to narrow: big pharma will no longer be shopping across therapeutic areas generically.
Hengrui's $600 million upfront from BMS is also notable because it reverses historical deal direction. Ten years ago, this deal would have been structured as U.S. pharma licensing to China. Now it is China licensing early oncology programs to the West. Practitioners building oncology platforms in Asia should expect inbound interest from top-tier U.S. acquirers.